

<b>Alert</b>	Watch for apnoeas and abdominal distension following administration. Lower concentration solutions and regimens minimising number of additional drops are recommended.
<b>Indication</b>	Induction of mydriasis and cycloplegia for diagnostic and therapeutic ophthalmic procedures.
<b>Action</b>	Anticholinergic drug that produces pupillary dilatation by inhibiting the sphincter pupillae muscle and paralysis of accommodation.
<b>Drug Type</b>	Antimuscarinic.
<b>Trade Name</b>	Minims Tropicamide Eye Drops Mydriacyl Eye drops
<b>Presentation</b>	Minims Tropicamide Eye Drops 0.5%, 1.0% solution. Mydriacyl Eye drops 0.5%, 1.0% 15 mL (multidose—excipients benzalkonium chloride 0.01%, sodium chloride, disodium edetate, hydrochloric acid and/or sodium hydroxide, purified water).
<b>Dosage/Interval</b>	Use in combination with phenylephrine 2.5% with or without cyclopentolate 0.5%.  <b>REGIMEN 1:</b> Phenylephrine 2.5% + cyclopentolate 0.5% + tropicamide 0.5% eye drops [1-4]. Instil one drop of each agent (5 minutes apart) into each eye 60 minutes prior to examination. Repeat if pupillary dilatation inadequate. Perform examination 60 to 120 minutes after instillation.  <b>REGIMEN 2:</b> Phenylephrine 2.5% + tropicamide 0.5% eye drops [5-7]. Instil one drop of each agent (5 minutes apart) into each eye 60 minutes prior to examination. Repeat if pupillary dilatation inadequate. Perform examination 60 to 120 minutes after instillation.  Dark irides may require additional drops.
<b>Maximum daily dose</b>	REGIMEN 1: 3 drops of each agent. REGIMEN 2: 4 drops of each agent.
<b>Route</b>	Topical instillation into the eyes from the container or use a microdrop (5–7 microL) cannula.
<b>Preparation/Dilution</b>	
<b>Administration</b>	Apply pressure to the lacrimal sac during and for 60 seconds after instillation of eye drop to minimise systemic absorption. Wipe away excess medication. Consider withholding feeds for four hours from administration of the last drops to reduce incidence of feed intolerance.
<b>Monitoring</b>	Blood pressure, heart rate, oxygen saturation in infants with bronchopulmonary dysplasia or at risk of apnoea. Signs of ileus.
<b>Contraindications</b>	Necrotising enterocolitis (NEC) at the time of examination.
<b>Precautions</b>	Bronchopulmonary dysplasia. Severe neurological impairment—may increase risk of seizures. Feeding intolerance. Lower concentration solutions and regimens minimising number of additional drops are recommended to minimise toxicity.
<b>Drug Interactions</b>	Cyclopentolate, phenylephrine, tetracaine (amethocaine)
<b>Adverse Reactions</b>	Feeding intolerance, abdominal distension and increased gastric residuals. Apnoea, transient bradycardia (especially infants on respiratory support). Stinging or burning of eye. Rarely dry mouth, urinary retention, fever, tachycardia, vasodilatation, restlessness, agitation, seizures.
<b>Compatibility</b>	Phenylephrine, cyclopentolate, tetracaine (amethocaine)
<b>Incompatibility</b>	No information.

<b>Stability</b>	Discard immediately after use.
<b>Storage</b>	Store in refrigerator at 2°C to 8°C. Do not freeze. Protect from light.
<b>Special Comments</b>	Without lacrimal sac occlusion, approximately 80% of each drop may pass through the nasolacrimal system and be available for rapid systemic absorption by the nasal mucosa. Consider withholding feeds for four hours from administration of the last drops. Used in conjunction with topical anaesthetic, e.g. tetracaine (amethocaine).
<b>Evidence summary</b>	Refer to full version.
<b>References</b>	Refer to full version.

<b>Original version Date: 13/03/2018</b>	<b>Author: NMF Consensus Group</b>
<b>Current Version number: 1.0</b>	<b>Current Version Date: 13/03/2018</b>
<b>Risk Rating: Medium</b>	<b>Due for Review: 13/03/2021</b>
<b>Approval by: JHCH CQ&amp;PCC</b>	<b>Approval Date: 24/07/2018</b>

**Authors Contribution**

Original author/s	Himanshu Popat
Expert review	Mark Jacobs, Hughie Tsang, Kimberley Tan
Evidence Review	David Osborn
Nursing Review	Eszter Jozsa
Pharmacy Review	Jing Xiao, Mariella De Rosa
Final content and editing review of the original	Ian Whyte
Electronic version	Mariella De Rosa, Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty